Salarius Pharmaceuticals, Inc. (SLRX)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 116,383 | |||
| General and administrative | 849,182 | |||
| Total operating expenses | 965,565 | |||
| Loss before other income (expense) | -965,565 | |||
| Interest income, net | 7,740 | |||
| Loss from continuing operations | -957,825 | |||
| Net loss | -957,825 | |||
| Loss per common share, basic ( in dollar per share) | -0.45 | |||
| Loss per common share, diluted ( in dollar per share) | -0.45 | |||
| Weighted average number of shares outstanding, basic (in shares) | 2,122,872 | |||
| Weighted average number of shares outstanding, diluted (in shares) | 2,122,872 | |||